In collaboration with Moderna ( NASDAQ:MRNA ), a biotech company, the University of Texas has been awarded a contract from the U.S. Department of Defense (DoD)) for up to $25 million to develop vaccinations against biological threats like Ebola.
According to the terms of the three-year contract, the University of Texas Medical Branch (UTMB) would receive $13.5 million from the DoD for the creation of filovirus vaccines that will be used in a Phase 1 study to combat the Edo (EBOV), Sudan (SUDV), Marburg (MARV), and Lassa (LASV) viruses.
In order to design, create, and test the vaccine candidates, UTMB will work with Moderna (MRNA) and their messenger RNA platform. If alternatives are used for other activities, such as different immunization routes, the project also provides up to $11.1 million in additional financing.
Filovirus outbreaks are caused primarily in Central and West Sub-Saharan Africa by EBOV, SUDV, and MARV. There isn’t a vaccine for Ebola that has been licensed as of yet.
Moderna Stock Forecast
Moderna stock went up in October as word spread of an expected deal with the US to make vaccines based on messenger RNA to fight biological threats like Ebola.
Bernie Sanders Cautions Moderna About Pricing Increases
In a letter to Moderna Inc. this week, U.S. Senator Bernie Sanders urged the pharmaceutical company to post...
Click here to read the full article on PressReach.com .Subscribe to the PressReach RSS feeds:
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Follow PressReach on TikTok
Follow PressReach on Instagram
Subscribe to us on Youtube